Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | METAP1 | P53582 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6383092 | 0.90 | ALDH1A1 (0.70) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL972021 | 0.87 | CYP24A1 (0.53) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL7290713 | 0.87 | CYP24A1 (0.53) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL2466607 | 0.86 | METAP1 (0.53) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL8036388 | 0.84 | KMT2A (0.74) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL8046948 | 0.83 | ALDH1A1 (0.72) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL2061479 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL15825184 | 0.83 | KMT2A (0.72) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL27236981 | 0.83 | KMT2A (0.72) | ALDH1A1KDM4EKMT2AMEN1GAA | |
| SCHEMBL4726216 | 0.81 | KDM4E (0.78) | ALDH1A1KDM4EKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047701-B1 | MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN BIOTECHNOLOGY LTD (NZ) | 2005-05-25 | — | — | EP | claimed |
| EP-0910370-B1 | COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING UVEITIS | CENTAUR PHARMACEUTICALS INC (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2008057309-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057309-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1819656-A2 | SYNTHESIS OF 1,5-DISTRIBUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | disclosed |
| EP-1047674-B1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | EISAI CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| EP-0813537-B1 | PHOSPHORYLATED NITRONE DERIVATIVES, METHOD FOR PREPARING SAME, AND COMPOSITIONS CONTAINING SAID DERIVATIVES | CENTRE NAT RECH SCIENT (FR) | 2002-06-26 | — | — | EP | disclosed |
| EP-1047674-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0991772-A1 | METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS | Biocatalytics, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999036405-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVE | EISAI CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| WO-1998054350-A1 | METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS | BIOCATALYTICS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0813537-A1 | PHOSPHORYLATED NITRONE DERIVATIVES, METHOD FOR PREPARING SAME, AND COMPOSITIONS CONTAINING SAID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027601-A1 | PHOSPHORYLATED NITRONE DERIVATIVES, METHOD FOR PREPARING SAME, AND COMPOSITIONS CONTAINING SAID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094779-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ALDH1A1 1917/4885KDM4E 2393/4885KMT2A 1108/4885 |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | ESR1, GPER1, CYP19A1 | ALDH1A1 305/4885KDM4E 454/4885KMT2A 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.